These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34117140)

  • 1. Effect of Genetic Polymorphism of the CYP2D6 Gene on the Efficacy and Safety of Fluvoxamine in Major Depressive Disorder.
    Zastrozhin M; Skryabin V; Smirnov V; Zastrozhina A; Grishina E; Ryzhikova K; Bure I; Golovinskii P; Koporov S; Bryun E; Sychev D
    Am J Ther; 2021 Jun; 29(1):e26-e33. PubMed ID: 34117140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration of Phenazepam in Patients with Recurrent Depressive Disorder.
    Zastrozhin MS; Efimova AV; Skryabin V; Smirnov VV; Petukhov AE; Pankratenko EP; Pozdniakov SA; Kaverina EV; Klepikov DA; Grishina EA; Ryzhikova KA; Bure IV; Bryun EA; Sychev DA
    Psychopharmacol Bull; 2021 Nov; 51(4):87-104. PubMed ID: 34887601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Influence of Concentration of Micro-RNA hsa-miR-370-3p and CYP2D6*4 on Equilibrium Concentration of Mirtazapine in Patients With Major Depressive Disorder.
    Zastrozhin ; Smirnov ; Petukhov ; Pankratenko ; Zastrozhina ; Grishina ; Ryzhikova ; Bure ; Skryabin ; Vlasovskih ; Bryun ; Sychev
    Psychopharmacol Bull; 2020 Jul; 50(3):58-75. PubMed ID: 32733112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the Omics-Based Biomarkers on the Fluvoxamine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder.
    Zastrozhin MS; Skryabin V; Smirnov V; Zastrozhina AK; Kaverina EV; Klepikov DA; Grishina EA; Ryzhikova KA; Bure IV; Bryun EA; Sychev DA
    Psychopharmacol Bull; 2021 Jan; 51(1):69-80. PubMed ID: 33897064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Polymorphism of CYP2D6 on Equilibrium Concentration of Duloxetine in Patients Suffering from Major Depressive Disorder.
    Zastrozhin ; Petukhov ; Pankratenko ; Grishina ; Ryzhikova ; Skryabin ; Koporov ; Bryun ; Sychev
    Psychopharmacol Bull; 2020 Jul; 50(3):47-57. PubMed ID: 32733111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of plasma concentration of micro-RNA Mir-27b and CYP3A4*22 on equilibrium concentration of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder.
    Zastrozhin MS; Skryabin VY; Smirnov VV; Petukhov AE; Pankratenko EP; Zastrozhina AK; Grishina EA; Ryzhikova KA; Bure IV; Golovinskii PA; Koporov SG; Bryun EA; Sychev DA
    Gene; 2020 May; 739():144513. PubMed ID: 32112986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of CYP2D6 Polymorphism on Equilibrium Concentration of Fluoxetine in Patients Diagnosed With Major Depressive Disorder and Comorbid Alcohol Use Disorders.
    Zastrozhin MS; Skryabin VY; Petukhov AE; Pankratenko EP; Grishina EA; Ryzhikova KA; Torrado MV; Shipitsyn VV; Bryun EA; Sychev DA
    J Psychiatr Pract; 2021 Sep; 27(5):372-379. PubMed ID: 34529603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder.
    Zastrozhin MS; Skryabin V; Smirnov V; Zastrozhina AK; Kaverina EV; Klepikov DA; Grishina EA; Ryzhikova KA; Bure IV; Bryun EA; Sychev DA
    Psychopharmacol Bull; 2021 Mar; 51(2):31-42. PubMed ID: 34092821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder.
    Zastrozhin MS; Grishina EA; Denisenko NP; Skryabin VY; Markov DD; Savchenko LM; Bryun EA; Sychev DA
    Pharmgenomics Pers Med; 2018; 11():113-119. PubMed ID: 29988737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder.
    Zastrozhin MS; Skryabin VY; Smirnov VV; Grishina EA; Ryzhikova KA; Chumakov EM; Bryun EA; Sychev DA
    Can J Physiol Pharmacol; 2019 Aug; 97(8):781-785. PubMed ID: 31100205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of the
    Parkhomenko AA; Zastrozhin MS; Skryabin V; Petukhov AE; Pozdniakov SA; Ivanchenko VA; Zaytsev IA; Bure IV; Bochkov PO; Akmalova KA; Smirnov VV; Bryun EA; Sychev DA
    Psychopharmacol Bull; 2023 Dec; 53(4):15-22. PubMed ID: 38076663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of
    Zastrozhin M; Skryabin V; Petukhov A; Pankratenko E; Pozdniakov S; Ivanchenko V; Horyaev D; Vlasovskih R; Bryun E; Sychev D
    J Psychopharmacol; 2022 Oct; 36(10):1146-1150. PubMed ID: 35861192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration.
    Sychev DA; Zastrozhin MS; Miroshnichenko II; Baymeeva NV; Smirnov VV; Grishina EA; Ryzhikova KA; Mirzaev KB; Markov DD; Skryabin VY; Snalina NE; Nosikova PG; Savchenko LM; Bryun EA
    Drug Metab Pers Ther; 2017 Sep; 32(3):129-136. PubMed ID: 28787271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of
    Parkhomenko AA; Zastrozhin MS; Skryabin V; Ivanchenko VA; Pozdniakov SA; Noskov VV; Zaytsev IA; Denisenko NP; Akmalova KA; Bryun EA; Sychev DA
    Psychopharmacol Bull; 2022 Jun; 52(3):58-67. PubMed ID: 35815171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of
    Parkhomenko AA; Zastrozhin MS; Pozdnyakov SA; Noskov VV; Zaytsev IA; Ivanchenko VA; Denisenko NP; Akmalova KA; Skryabin V; Bryun EA; Sychev DA
    Psychopharmacol Bull; 2022 Oct; 52(4):52-60. PubMed ID: 36339274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction.
    Sychev DA; Zastrozhin MS; Smirnov VV; Grishina EA; Savchenko LM; Bryun EA
    Pharmgenomics Pers Med; 2016; 9():89-95. PubMed ID: 27695358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients.
    Suzuki Y; Sawamura K; Someya T
    Neuropsychopharmacology; 2006 Apr; 31(4):825-31. PubMed ID: 16205777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder.
    Zastrozhin MS; Skryabin VY; Petukhov AE; Torrado MV; Pankratenko EP; Zastrozhina AK; Grishina EA; Ryzhikova KA; Shipitsyn VV; Bryun EA; Sychev DA
    Pharmacogenomics J; 2021 Aug; 21(4):435-439. PubMed ID: 33608663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.
    Gerstenberg G; Aoshima T; Fukasawa T; Yoshida K; Takahashi H; Higuchi H; Murata Y; Shimoyama R; Ohkubo T; Shimizu T; Otani K
    Psychopharmacology (Berl); 2003 Jun; 167(4):443-8. PubMed ID: 12682708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
    Otsubo T; Akimoto Y; Yamada H; Koda R; Aoyama H; Tanaka K; Mimura M; Nakagome K; Kamijima K
    Pharmacopsychiatry; 2005 Jan; 38(1):30-5. PubMed ID: 15706464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.